Gt Biopharma, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
GT Biopharma, Inc. has filed a Definitive Proxy Statement (DEFA14A) with the U.S. Securities and Exchange Commission.
NASDAQ
GT Biopharma, Inc. is calling its stockholders to an Annual Meeting on July 24, 2025, to vote on critical proposals including the election of directors, ratification of auditors, an advisory vote on executive compensation, and, most notably, the approval of substantial share issuances and an expansion of its equity incentive plan.
NASDAQ
GT Biopharma reminds stockholders holding 100 or more shares to vote before the upcoming Annual Meeting on June 25, 2024.
NASDAQ
GT Biopharma has filed a definitive proxy statement with the SEC.
NASDAQ
GT Biopharma will hold its annual stockholders meeting virtually on June 25, 2024, to vote on the election of directors, ratification of independent accountants, and executive compensation.